I'm not short. I've never shorted a stock in my life. How come every time someone posts a comment about a legitimate concern about a stock, people think they're short?
Last year I originally bought at $6.50, after they did a raise, and kept averaging down and down and down. Sold for a decent profit when it moved up over $5 and bought back around $4 when the share price looked like it was stabilizing. I'm sitting with shares averaged at $4. I'm just sitting here watching this and the chart is looking eerily familiar when it slowly dripped from $6.50 to low $2s and I don't want to be caught sitting in it again. That's my fear.
I sure hope that I'm not caught in this when they do a raise. I think the market is already skeptical about the company, and definitely skeptical of Steve K (as they should be). Any raises down around this area will see the stock price get a major haircut, imo. Unless they can somehow get the share price at a much higher level in the next little while, we could be in trouble. Given that the share price doesn't react well to news, my guess is that they'll be left with no choice but to raise at these low levels. I hope I'm wrong. My frustration levels with the share performance are hitting all time highs. I just need to vent.
Anyone else here confused as to why CYTR just can't get any Wall St. love? It seems to be that based on all of the news we've been receiving the past few months this should not be as low as it is, yet here we sit. We have 7 institutions with anywhere from 1.3 to 5.2 million shares, a world renowned researcher in Dr. Kratz, no insider sells, law suits being cleaned up, Buys and Outperform ratings with price targets from $6-10, 22% held by insiders and 39% held by institutions. I'd like to think we're over the Dream Team fiasco but I really think that having Steve K at the helm severely discredits this company. He's looked at as a #$%$ and scam artist and as long as he's at the helm, I think we're going to have a hard time making any serious gains until at least 2H of 2016.
Next Generation Linker Technology Designed to Improve the Safety and Efficacy of Oncology Therapies, Including Immunotherapies and High Potency Chemotherapeutics up to 1,000 Times More Powerful than Traditional Drugs First Drugs Derived from CytRx's LADR™ Platform Expected to Enter Clinical Development in 2016
PR Newswire CytRx Corporation
LOS ANGELES, June 30, 2015 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today unveiled its proprietary LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage the Company's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies. CytRx expects the LADR™ platform to rapidly expand its pipeline of oncology drug candidates, providing an avenue for the development of propriety drug candidates that complement its global Phase 3 aldoxorubicin program. Among the cancers being pursued are liver, pancreatic, and non-small cell lung cancer.
"LADR™ is a creative, novel approach to the development of next-generation therapeutic drug conjugates, which we have rationally designed to control release in tumors of high-potency chemotherapeutics that are attached to either albumin or anti-cancer antibodies," stated Dr. Felix Kratz, Vice President of Drug Discovery at CytRx. "These therapies have release properties that minimize their toxic effects on non-cancerous cells, may substantially reduce drug resistance and maximize their anti-cancer potency. With the first drug candidates from this platform expected to enter the clinic in 2016, we look forward to further validating the great potential of this platform in the near future. Our LADR™ Technology can also be easily combined with immunotherapies to potentially improve outcomes."
"CytRx is committed to improving and extending the lives of patients with cancer through the development of new and innovat
They couldn't have picked a worse week to update the market.
Clinical Trial Data Shows 78% of Patients Demonstrated a Partial ResponseAldoxorubicin Was Well Tolerated in the Clinical Trial and Results Show Uptake of Doxorubicin in KS LesionsData to be Presented at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus
LOS ANGELES, June 29, 2015 /PRNewswire/-- CytRx Corporation CYTR, -1.57% a biopharmaceutical research and development company specializing in oncology, today announced the presentation of interim results from its ongoing open-label Phase 2 pilot study evaluating the efficacy and safety of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients. The data will be presented on Wednesday, July 1, 2015 during a poster session at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents in Hollywood, Florida.
For the study, patients with biopsy-confirmed KS were administered 100 or 150 mg/m2 aldoxorubicin (75 or 112 mg/m2 doxorubicin equivalents) IV every three weeks. At the time of presentation, preliminary analyses were available for nine patients who received at least six cycles of drug (mean = 6.3 cycles). Four patients had received prior Doxil chemotherapy. Of these 9 patients, 6 (67%) demonstrated a partial response (PR) to aldoxorubicin at the end of study visit (EOS), and 7 (78%) demonstrated PR within 4 months of EOS. Doxorubicin could be detected in all tumor biopsies and higher doxorubicin concentrations were demonstrated within KS lesions relative to skin next to the lesions for 3/4 (75%) patients for whom adequate tissue was available for analysis. Five of 6 (83%) patients receiving aldoxorubicin and for whom data are available exhibited reduced intratumoral viral loads during therapy. A subset of patients also exhibited improvements in quality of life during treatment, and all patien
Dude, you're preaching the the choir here. Almost everyone on this board has been around a while and knows that the management is shady, especially the CEO. The Dream Team fiasco is long in the past and to bring it up is irrelevant at this time.
You're wasting a lot of time poking the bear here. If you were thinking of buying shares but not any more, then move along. If you're going to buy, buy. Today's as good a day as any seeing that the share price is in the low 3.90s.
I hope we see some very good news soon that sees this sustain a nice upward trend. All pops on news tend to get sold into hard and this has a hard time making any serious gains.
It's the same guy that has about 4 other aliases. You block them and there's not much other conversation going on on this board.
went from looking like it was ready to curl up and explode with volume and some how it completely reversed. Even today with the market staging a comeback CYTR is making new lows. I know it's been on low volume, but still... what gives...
It just ain't gonna happen. This is dead money for a while unless they come out with some surprise updates.
And they just did the exact same thing a few months back issuing free options when the stock was around $2.30!!
Good buy. You won't find much discussion happening here, or any message board for that matter. That won't last long though...